Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
-
Published:2023-03
Issue:
Volume:385
Page:104675
-
ISSN:0008-8749
-
Container-title:Cellular Immunology
-
language:en
-
Short-container-title:Cellular Immunology
Author:
Bertolini Thais B.,
Herzog Roland W.ORCID,
Kumar Sandeep R.P.,
Sherman Alexandra,
Rana Jyoti,
Kaczmarek Radoslaw,
Yamada Kentaro,
Arisa Sreevani,
Lillicrap David,
Terhorst Cox,
Daniell Henry,
Biswas Moanaro
Reference81 articles.
1. A. Iorio, J.S. Stonebraker, H. Chambost, M. Makris, D. Coffin, C. Herr, F. Germini, Data, H. Demographics Committee of the World Federation of, Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries, Ann. Intern. Med., 171 (2019) 540-546.
2. Innovative approaches for immune tolerance to factor VIII in the treatment of Hemophilia A;Sherman;Front. Immunol.,2017
3. Recombinant factor VIII in the management of hemophilia A: current use and future promise;Powell;Ther. Clin. Risk Manag.,2009
4. Factor VIII replacement is still the standard of care in haemophilia A;Aledort;Blood Transfus,2019
5. A molecular revolution in the treatment of Hemophilia;Butterfield;Mol. Ther.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献